Fundraising FoxAffinivax
Cambridge, US · Founded 2014 · 7 known investors
Find your way into Affinivax
Sign up to see every warm intro you have to Affinivax
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Affinivax team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology. The company has been acquired by GSK.
Founders & leadership
Affinivax was founded in 2014 by Richard Malley.
Board
Investors · 7
How we know: Bain Capital Life Sciences's portfolio page · board seat on SEC Form D · Not right? Tell us
How we know: Foresite Capital's portfolio page · a partner's Signal profile · funding news · Not right? Tell us
How we know: Viking Global's portfolio page · Not right? Tell us
How we know: funding news · baincapital.com · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$233M disclosed across 2 of 3 rounds · 2017–2021
▶$226MraisedJan 2021 · 27 investors · BiotechnologyRule 506(b)
- Richard MalleyDirector
- Frances HellerDirector
- Steven BruggerExecutive Officer, Director
- Robert MoreDirector
- George SiberDirector
- Steven AltschulerDirector
- Andrew HackDirector
- Offering amount
- $226M
- Amount sold
- $226M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7MraisedJan 2018 · 5 investors · BiotechnologyRule 506(b)
- Richard MalleyDirector
- Robert MoreDirector
- Frances HellerDirector
- Kamran TavangarExecutive Officer
- George SiberDirector
- Steven BruggerExecutive Officer, Director
- Offering amount
- $7M
- Amount sold
- $7M
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Affinivax do?
- Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology. The company has been acquired by GSK.
- Who founded Affinivax?
- Affinivax was founded by Richard Malley in 2014.
- Who are Affinivax's investors?
- Affinivax's investors include Bain Capital Life Sciences, EcoR1 Capital, Foresite Capital, Viking Global, Bain Capital, Rock Springs Capital, T. Rowe Price.
- How much funding has Affinivax raised?
- Affinivax has disclosed $233M raised across 2 of its 3 known rounds.
- Where is Affinivax headquartered?
- Affinivax is headquartered in Cambridge, US.